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ABSTRACT
Hematologic complete remission (CR) is
achievable for most adults with B cell precursor
acute lymphoblastic leukemia (BCP-ALL).
However, minimal residual disease (MRD) in
patients with hematologic CR is associated with
increased risk of relapse, shorter survival, and
poorer transplantation outcomes. This study
explored the concept of cure in adults with
Philadelphia chromosome-negative (Ph-) BCP-
ALL by MRD status at first hematologic CR
(CR1) to inform evaluation of the clinical and
economic benefits of new agents, where the
concept of cure is important but long-term data
are not available. The study used modified
Delphi methodology involving clinicians expe-
rienced in the treatment of adult ALL. Partici-
pants completed a questionnaire, which was
followed by country-specific panel discussions
to discuss results and identify consensus on
concepts and definitions. Clinicians from
France (n = 4), Germany (n = 4), and the UK
(n = 5) took part. Participants described cure in
terms of the probability of future relapse.
Relapse-free survival (RFS) was the preferred
outcome measure to describe cure for the three
patient groups considered (patients with MRD
at CR1; patients who become negative for MRD
after further treatment; patients who continue
to have MRD). Consensus was reached on defi-
nitions of cure: that cure would begin to be
considered at 3 years’ RFS and/or would be
highly likely at 5 years’ RFS. Participants agreed
that patients with MRD should usually undergo
hematopoietic stem cell transplantation to have
the best chance of survival; consensus was
reached that alternatives are required when
transplantation is not an option. Panels agreed
that patients who achieve cure have a higher
mortality rate and lower health-related quality
of life than the general population. This study
provides quantitative and qualitative informa-
tion on the concept of cure in Ph- BCP-ALL in
CR by MRD status applicable to interpreting the
value of new therapies.
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PLAIN LANGUAGE SUMMARY
Acute lymphoblastic leukemia (ALL) is a blood
cancer caused by abnormal white blood cells in
the bone marrow. Patients with ALL are given
chemotherapy to destroy the abnormal cells,
but in some patients a small number of abnor-
mal cells remain that cannot be detected by
conventional methods. The risk of disease
returning is greater for these patients than for
patients without residual abnormal cells.
New therapies are being introduced for ALL
that may help patients to achieve cure, but
there is no clear agreement on how cure should
be defined. To find out, we asked the opinions
of specialists to see if they could reach a con-
sensus. As the presence of residual abnormal
cells increases the likelihood that ALL will
return, we asked these specialists to consider
groups of patients with and without these cells.
The specialists agreed that:
• The length of time that patients continued
without their disease returning was impor-
tant in deciding whether the disease was
likely to be cured.
• Patients (with and without residual abnor-
mal cells) are considered likely to be cured
after 3–5 years of their disease not returning.
• Patients with residual abnormal cells should
usually undergo stem cell transplantation to
have the best chance of survival.
• Patients who are cured have poorer health
and a higher risk of dying than people who
have not had ALL.
The information gained from this study will
help interpret evidence from clinical trials by
suggesting which long-term outcomes of
patients treated with new therapies are most
meaningful.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a rare
hematologic malignancy that shows bimodal
incidence, with most cases occurring in chil-
dren (80%), followed by a gradual increase in
incidence after 50 years of age [1, 2]. Approxi-
mately three-quarters of adult ALL cases are of B
cell lineage, the majority originating from B
lymphocyte precursors (BCP-ALL) [3].
For most adults with ALL, front-line
chemotherapy will result in hematologic com-
plete remission (CR) (based on morphologic
assessment), which is a prerequisite, but by itself
not sufficient, for cure. Patients who achieve
hematologic CR can potentially harbor leu-
kemic cells in the bone marrow. The presence of
leukemic cells that are below the threshold of
detection by conventional morphologic meth-
ods is referred to as minimal residual disease
(MRD).
Large-scale analyses have shown a strong
association between the presence of MRD after
front-line chemotherapy and poor long-term
outcomes, including increased risk of relapse
and shorter relapse-free and disease-free survival
[4–8]. European clinical guidelines therefore
recommend testing patients in first hematologic
complete remission (CR1) for MRD for the pur-
pose of risk stratification [9], and this is reflected
in national protocols for the treatment of adult
ALL. This risk stratification dictates whether
immediate (allogeneic) hematopoietic stem cell
transplant (HSCT) is indicated for a given
patient, because of a higher risk of relapse, or
whether that patient should receive additional
chemotherapy, because the lower risk of relapse
would outweigh the mortality and morbidity
associated with HSCT. Nevertheless, the current
European guidelines lack deep clarity on the
most appropriate use of MRD status and other
prognostic factors for clinical decision-making
in adults. In addition, the designated MRD sta-
tus of an individual patient may be influenced
by the detection technology and the time point
of measurement. Decisions about treatment are
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further complicated by the recent approvals of
immunotherapies for the treatment of adults
with ALL (including blinatumomab, ino-
tuzumab ozogamicin, and chimeric antigen
receptor T cell therapy), as it is not yet clear how
HSCT should be used in future treatment path-
ways incorporating these agents.
The concept of cure has been highlighted as
particularly important when assessing the
value of immunotherapies, for which treat-
ment outcomes suggest that cure may be an
increasingly achievable goal [10–12]. The long-
term survival of patients who have received a
new treatment versus the standard of care
(SOC) is frequently critical to quantify poten-
tial clinical and economic benefits; however,
data over longer time frames are rarely avail-
able, necessitating estimation of long-term
outcomes using assumptions informed by
expert opinion. Specifically, this includes
understanding after what time point it may be
assumed that patients will continue to survive
in the long term, and what will be their long-
term health status. This study was initiated to
provide such estimates for patients in first
hematologic CR in a transparent and method-
ologically sound manner, in the absence of
previously published findings for this patient
population.
Given the demonstrable prognostic implica-
tions of MRD in patients with BCP-ALL, this
study aimed to use MRD status as the basis to
explore concepts of cure, with the focus on
adults with Philadelphia chromosome-negative
(Ph-) BCP-ALL. Patients with Ph? BCP-ALL
were not considered in this study, as this group
represents a minority with its own specific
treatment pathways (including the use of tyr-
osine kinase inhibitors) and a distinctly differ-
ent prognosis. This study also aimed to
understand clinicians’ perspectives on the rela-
tionship between HSCT and cure, specifically
whether HSCT is required for a patient to be
considered ‘‘cured’’ in current clinical practice.
Further, the study aimed to elicit estimates of
the proportion of patients who meet specialists’
own definitions of cure in current clinical
practice, and to garner understanding of the
long-term prognoses of these patients (in terms
of mortality and health-related quality of life,
HRQL).
Several of these questions were deemed to be
best answered through exploration of expert
opinion from clinicians currently treating
patients with ALL. Therefore, a consensus
approach widely applied in health service
research—Delphi methodology—was used for
this study.
Representatives from five countries were
included in this study: France, Germany, Italy,
the UK, and Australia. It was considered valu-
able to gather country-specific insights into
these various concepts, particularly given the
differences between national protocols for adult
ALL and differences in actual clinical practice.
The clinical community treating adults with
ALL is small and specialist in nature, such that a
panel size of four or five experienced clinicians
per country was considered pragmatic and
appropriate. The findings based on data col-
lected in France, Germany, and the UK are
presented here, as the panels in these countries
described similar patterns of practice in treating
BCP-ALL and were aligned on definitions of
cure. The findings from Italy and Australia were
distinct in their definition of cure and will be
described in a separate publication.
This report therefore describes the findings
of this study for three European countries. In
summary, the study aimed to better understand
how cure can be defined in adult BCP-ALL for
patients in first complete hematological remis-
sion and in the context of clinical practice in
each country, to inform evaluation of the clin-
ical and economic benefits of emerging agents,
specifically immunotherapies.
METHODS
Design
The study used a modified Delphi methodology,
which is designed to reach consensus between
individuals using questionnaire-based surveys
[13]. The study had two phases: phase 1
involved the completion of a Word-based
questionnaire; phase 2 involved participation in
country-specific virtual panel discussions
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(including response gathering and voting). For
categorical questions about which consensus for
a given country could be evaluated (i.e., non-
descriptive questions), consensus was defined
by at least 80% of participants being in agree-
ment if five participants were involved (i.e., four
out of five participants). When panels involved
four participants, consensus was defined as 75%
agreement (i.e., three out of four participants).
Ethical approval for the study was received from
the Human Research Ethics Committee of the
University of Technology, Sydney, Australia,
and all participants provided informed consent.
Recruitment of Participants
The study aimed to recruit five participants
from each of the countries. However, as a result
of the limited availability of suitable partici-
pants, only four clinicians were recruited in
both France and Germany.
Participants were recruited if they met the
following inclusion criteria: board-certified or
specialized in hematology or hemato-oncology;
at least 5 years’ experience in this role after
completion of training; treats adults with ALL;
has seen at least two adults with ALL in the last
12 months, or at least five in the past 5 years;
regularly tests patients with ALL for MRD in
clinical practice; is able and willing to partici-
pate in the Delphi study; and is able to speak
and write English as assessed by the research
team during recruitment.
The identities of participants were kept con-
fidential during the study, including from the
study sponsor, to avoid potential bias.
Data Collection
In phase 1, participants completed Word-based
questionnaires sent via email. The question-
naire consisted of categorical, numerical, and
open-ended questions and included questions
related to background information about the
participants and their clinics; definition of cure;
cure rates and survival outcomes; and the roles
of allogeneic HSCT in achieving cure.
To understand the role of MRD status in the
concept of cure, participants were initially asked
to consider patients with Ph- BCP-ALL who
were MRD-positive at the first MRD test (defined
as the test after country-specific SOC induction
therapy, typically used to determine risk of
relapse and to establish the treatment plan for a
given patient) (population A; Fig. 1). Partici-
pants were then asked to consider the concept
of cure in two further patient populations: those
who are initially MRD-positive at CR1 but who
achieve MRD-negative status after subsequent
treatment, and those who are MRD-positive at
CR1 and remain so after subsequent treatment
(populations B and C, respectively; Fig. 1). Par-
ticipants were asked to define cure based on the
general concepts of cure in oncology outlined
by Johnson et al. [12], which were made specific
to ALL: absence of disease (interpreted as MRD-
negative status for patients with ALL at CR1),
relapse-free survival (RFS), and overall survival
(OS), with stratification for different MRD sce-
narios as described above. Questions were then
asked about mortality risk and HRQL in patients
with Ph- BCP-ALL who subsequently are con-
sidered to have achieved cure according to the
clinician’s previously elicited specific definition.
Phase 2 consisted of a series of country-
specific panel meetings conducted virtually
(through a web conference platform, with audio
and screen share capabilities). A summary of the
country-specific phase 1 results was provided as
input for the panel meetings. For questions
about which consensus was reached in phase 1,
no further discussion was facilitated in phase 2.
When there was no consensus in phase 1, facil-
itated discussion of the phase 1 results took
place, and when appropriate, additional partici-
pant responses were collected using an interac-
tive voting system; on occasion, data were
recorded manually. The voting involved pre-
senting participants with statements on a topic,
derived from phase 1 responses (either repeating
questions already asked in the questionnaire
after discussion had been completed or new
statements based on responses received). The
findings of the first panel meeting conducted (in
the UK) informed refinement of the statements
presented to subsequent panels. Participants
were then asked to indicate with which state-
ments they agreed. In some cases, participants
could choose more than one statement, while in
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other cases only one answer was permitted. In
France, one clinician was unable to attend the
panel discussion at the last minute. Therefore, in
this case, a one-to-one interview was conducted
at a later time: the points raised in the panel were
discussed, and the participant was asked to vote
on the same statements, without knowledge of
the responses from the other participants.
Data Analysis
Data fromphases1and2of the studywereentered
into Microsoft Excel, anonymized, and analyzed
to generate country-specific results. The analyses
involved determining frequencies for categorical
responses, using standard summary statistics for
numerical responses, and identifying common
themes from open-ended questions.
RESULTS
Demographics of Panel
A total of 13 clinicians from France (n = 4),
Germany (n = 4), and the UK (n = 5) took part
in the study. Nine participants were hematolo-
gists and four were hemato-oncologists. The
majority of the participants worked in a uni-
versity hospital (n = 10), two were from a des-
ignated cancer hospital or specialist oncology
center, and one was from a general (urban or
community) hospital. All participants were
working on clinical teams that conduct HSCT.
Overall, participants had a median of 20 years’
experience (range 10–30 years) in treating ALL
and treated a median of 14 patients (range 8–50)
with Ph- BCP-ALL per year.
Definition of Cure
Participants described the potential for cure in
terms of probability of relapse, rather than
providing a definitive definition (see ‘‘Box 1’’).
They considered this to be a more appropriate
way to discuss treatment goals and outcomes in
patients with ALL. Importantly, all panels noted
that a small minority of patients with ALL
experience late relapses, so cure could not be
defined with absolute certainty. In patients who
are MRD-positive at CR1, participants in all
countries described RFS as the preferred
Fig. 1 Patient populations deﬁned for this research. CR1 ﬁrst complete remission, MRD minimal residual disease, OS
overall survival, Ph– BCP-ALL Philadelphia-negative B cell precursor acute lymphocytic leukemia, RFS relapse-free survival
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outcome measure for cure. MRD-negative status
was described by some participants as an early
indicator or predictor of cure, and OS was gen-
erally not preferred to RFS (or these measures
were considered equivalent given the poor
prognosis of ALL after relapse). Similarly, par-
ticipants agreed that cure should be defined on
the basis of RFS in the other patient groups
(patients who are MRD-positive but subse-
quently became MRD-negative, population B,
and those who remain MRD-positive,
population C).
Participants considered the time frames
after which patients could be considered to be
cured (Table 1). Consensus was reached in
France and the UK that for patients who were
MRD-positive at the first MRD test, they would
begin to consider cure at 3 years’ RFS; in Ger-
many, consensus was reached that cure was
highly likely at 5 years’ RFS. Clinicians in each
country further agreed that the same defini-
tion applies for patients who are MRD-positive
but subsequently become MRD-negative
(population B). In all countries, consensus was
reached that cure is highly likely at 5 years’
RFS in patients who are MRD-positive and
subsequently remain MRD-positive (popula-
tion C). In the UK, participants also agreed
that they start to consider these patients to be
cured at 3 years’ RFS. UK panel respondents
felt it was more straightforward to define cure
for this patient group than for other groups,
because research indicates that median time to
clinical relapse is short (6–8 months) among
such patients.
Participants from France also reached con-
sensus on cure being highly likely if MRD-
negative status is sustained for 5 years in
patients who are MRD-positive at CR1 but
subsequently become MRD-negative (popula-
tion B). In addition to a definition of cure
based on RFS, participants from Germany also
reached consensus on a definition based on OS
at 5 years, for patients who are MRD-positive
but subsequently become MRD-negative
(population B).
Likelihood of Cure
Participants were asked what proportion of
patients who were MRD-positive at CR1
(population A) are likely to achieve cure with
the current local SOC. Participants considered
eligibility for HSCT as a critical factor that
influences survival. The estimated proportion
of patients who are MRD-positive at CR1 and
could expect to achieve cure ranged from
30% to 50% in those eligible for HSCT,
whereas the cure rate was felt to be consid-
erably lower in those ineligible for HSCT
(Table 2).
For patients who were MRD-positive at CR1
but subsequently became MRD-negative or
remained MRD-positive (populations B and C,
respectively), participants were asked to con-
sider the results of a meta-analysis of event-free
survival (EFS) and OS of adults, stratified by
MRD status, conducted by Berry et al. [14],
which reported EFS of approximately 75% for
MRD-negative individuals and approximately
26% for MRD-positive individuals at 3 years.
The majority of French participants agreed with
BOX1. PARTICIPANT COMMENTS
ON THE CONCEPT OF CURE
‘‘Most of the time we call ‘cured’ patients
those who are long-term survivors. These
patients are mostly MRD-negative, but there
is a group of patients who are MRD-positive
and still survive. Therefore, I will consider
mostly RFS over OS, as patients who are in
RFS are also overall survivors.’’ French
clinician
‘‘In my mind, cure is a very strong word
and has to be time dependent. I see cure in
my patients who remain relapse-free beyond
5 years, and for me there is no surrogate
marker to suggest that or earlier time point to
make that distinction between RFS and OS.’’
German clinician
‘‘Here we are talking about probabilities
someone is cured and looking at surrogate
markers for these probabilities. But there is a
distinction between probability and being
actually cured; cure is much more than that.’’
UK clinician
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the survival outcomes reported in the published
meta-analysis for patients who are MRD-posi-
tive but subsequently become MRD-negative
(population B; Table 2). In the other countries,
the majority of participants thought that this
patient population would have a lower rate of
survival. Consensus was reached among partic-
ipants from France and the UK that the current
survival outcomes for patients who are MRD-
positive and remain MRD-positive after subse-
quent therapy (population C; Table 2) were at
least as poor as those shown in the meta-anal-
ysis. German participants either suggested a
lower estimate of the proportion of such
patients who achieve cure or stated that those
Table 1 Time frame for considering cure, phase 2 results
Patient 
population Definition
Percentage of clinicians who 
agreed with each statement
France
N=4
Germany
N=4
UK
N=5
MRD-positive
at CR1
(A)
I begin to consider cure when MRD-negative status 
is sustained for 2 or 3 yearsa 50% 0% 60%
I begin to consider cure at 3 years’ RFS 75% 0% 80%
Cure is highly likely when MRD-negative status is 
sustained for 5 years 25% 25% 0%
Cure is highly likely at 5 years’ RFS 50% 100% 60%
Cure is highly likely at 5 years’ OS 0% 50% 0%
MRD-positive
but
subsequently 
became 
MRD-
negative
(B)
I begin to consider cure when MRD-negative status 
is sustained for 2–3 yearsb 50% 0% 60%
I begin to consider cure at 3 years’ RFS 75% 0% 80%
Cure highly likely when MRD-negative status is 
sustained for 5 years 75% 25% 40%
Cure is highly likely at 5 years’ RFS 50% 100% 80%
Cure is highly likely at 5 years’ OS 25% 75% 20%
MRD-positive
and
subsequently 
remained 
MRD-positive
(C)
I begin to consider cure at 3 years’ RFS 50% 0% 80%
Cure is highly likely at 5 years’ RFS 75% 100% 80%
Cure is highly likely at 5 years’ OS 25% 50% 0%
Cure is not possible in these patients 25% 0% 20%
The points of consensus are highlighted in orange. The time point stated was adapted according to the results obtained in
phase 1 of the study
CR1 ﬁrst complete remission, MRD minimal residual disease, OS overall survival, RFS relapse-free survival
a France, Germany: 2 years, UK: 3 years
b France, Germany: 2 years, UK: 3 years
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who remained MRD-positive could not be
cured.
Necessity of HSCT for Cure
Participants were asked to consider whether
patients could be cured without HSCT, and how
HSCT is used currently in clinical practice in
their respective countries. Results are provided
in Table 3 and participants’ comments in
‘‘Box 2’’.
Participants from all three countries agreed
that HSCT is the current SOC for patients who
are in CR1 and are MRD-positive (popula-
tion A). In France, participants also agreed that
cure is possible without HSCT in this popula-
tion; however, in Germany and the UK, con-
sensus was not reached. Clinicians noted in
panel discussions that a small proportion of this
patient group could achieve cure with
chemotherapy alone.
For the other two populations (populations B
and C), participants from all three countries
agreed that HSCT is not always an option and
that alternatives are required. It was noted in
the German panel discussion that the use of
haplo-identical donors minimized the
Table 2 Estimates for cure rate, phase 2 results
Patient
population
Estimates for cure rate
France Germany UK
MRD-positive
at CR1 and
eligible for
HSCT
50% 40–50% 30%
MRD-positive
at CR1 and
ineligible for
HSCT
20% 10–20% Lower than
for those
eligible
for
HSCT
(not
further
deﬁned)
MRD-positive
but
subsequently
became
MRD-
negative
Agreement
with the
results of
the meta-
analysis
(& 75%)
50–60% 30–50%
MRD-positive
and
subsequently
remained
MRD-
positive
Agreement
with the
results of
the meta-
analysis
(& 26%)
No
consensusa
Agreement
with the
results of
the meta-
analysis
(& 26%)
CR1 ﬁrst complete remission, HSCT hematopoietic stem
cell transplant, MRD minimal residual disease
a Two participants stated that these patients cannot be
cured, whereas the other two participants estimated a
10–20% cure rate for this patient population
BOX2. PARTICIPANT
COMMENTS ON THE NECESSITY
OF HSCT FOR CURE
‘‘We do not fully know at the moment,
because we have new tools in trials such as
immunotherapies, but we do not know
whether MRD negativity after immunother-
apy has the same prognostic impact as MRD
negativity after HSCT.’’ French clinician
‘‘A very small number of patients who are
MRD-positive can be cured with conven-
tional chemotherapy, perhaps about 10%.
Allograft is better.’’ UK clinician
‘‘There is probably no need for transplan-
tation for these very few patients who became
MRD-negative after previously being positive
without transplantation.’’ UK clinician
‘‘HSCT is the option which you would
offer to patients. Most of the patients will
have either matched related or unrelated
donor; for those who do not have matched
donor, the gap will be closed with offering
haploid identical transplantation, so virtually
everyone will have a donor.’’ German
clinician
‘‘HSCT is for now the SOC for this group
(patients who are MRD-positive at CR1). I
hope this changes in the future. For now, if it
is possible, I still look for a transplant.’’
French clinician
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proportion of patients in their clinical practices
who were not able to undergo HSCT because of
lack of a donor. Consensus was not reached in
any country as to whether HSCT was essential
for cure in those who became MRD-negative. In
France and Germany, consensus was reached
Table 3 Requirement for HSCT to achieve cure, phase 2 results
Patient 
population Definition
Country
France Germany UK
MRD-positive
at CR1
HSCT is standard of care in this patient group 75% 100% 100%
HSCT is essential for cure this patient population 25% 50% 0%
Cure is possible without HSCT in this population 75% 50% 40%
MRD-positive
but
subsequently 
became 
MRD-
negative
HSCT is not always a treatment option and 
alternatives are required 100% 100% 100%
HSCT is essential to cure this patient population 50% 50% 20%
Cure is possible without HSCT in this population 50% 50% 60%
MRD-positive
and
subsequently 
remained 
MRD-positive
HSCT is not always a treatment option and 
alternatives are required 100% 100%
Not asked 
in the UK
HSCT is essential to cure this patient population 75% 75% Not asked in the UK
Cure is possible without HSCT in this population 25% 25% Not asked in the UK
The points of consensus are highlighted in orange
CR1 ﬁrst complete remission, HSCT hematopoietic stem cell transplant, MRD minimal residual disease
Table 4 Mortality and HRQL in patients who achieve cure, phase 2 results
Patient population Definition
Country
France Germany UK
MRD-positive but
subsequently 
achieved cure
Mortality rate 
higher than in 
general 
population 
Yes, all patients 
cured 75% 100% 100%
Yes, patients cured 
and who underwent 
HSCT
100% 75% 100%
Mortality rate 
following HSCT
2–3 times higher 50% 25% 20%
3–4 times higher 50% 25% 80%
More than 4 times 
higher 0% 50% 0%
HRQL Lower than general population 75% 100% 100%
The points of consensus are highlighted in orange
CR1 ﬁrst complete remission, HRQL health-related quality of life, HSCT hematopoietic stem cell transplant, MRD
minimal residual disease
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that HSCT was essential for cure in those who
remained MRD-positive.
Participants in all three countries speculated
that in the future, the introduction of
immunotherapies could provide the prospect of
cure without the need for HSCT; however, they
noted that, at present, evidence of the long-
term effectiveness of such therapies is lacking.
Impact of Treatment on Mortality
Participants were asked how the mortality rate
of patients with Ph- BCP-ALL who were MRD-
positive, but subsequently achieved cure, com-
pared with that in the age- and gender-matched
general population.
Consensus was reached in all three countries
that the mortality rate in patients who achieve
cure is higher than that in the age- and gender-
matched general population. The phase 1
questionnaire referred to a study by Martin et al.
that detailed the long-term mortality risk fol-
lowing HSCT in a US treatment center as being
four to nine times higher than that of the gen-
eral population [15]. In France and the UK,
there was consensus that the mortality rate
following HSCT was not more than four times
higher than in the general population, reflect-
ing improvements in post-transplant surveil-
lance and supportive care since the study by
Martin et al. Consensus was not reached in
Germany on whether mortality was more or less
than four times higher.
Impact of Treatment on HRQL
Participants were asked to consider the HRQL of
patients with Ph- BCP-ALL who were MRD-
positive but subsequently achieved cure. Results
are provided in Table 4 and participants’ com-
ments in ‘‘Box 3’’.
Consensus was reached in all three countries
that HRQL would be lower in cured patients
than in the age- and gender-matched general
population. This was stated as primarily being
due to chemotherapy- and HSCT-related com-
plications, such as GVHD; the latter was iden-
tified by some participants as the critical
determinant of the HRQL of patients after
transplantation. Other factors that were identi-
fied as detrimental to HRQL in those who
achieved cure included prolonged time in
BOX3. PARTICIPANT
COMMENTS ON THE IMPACT
OF TREATMENT ON HRQL
‘‘Beyond 3 years after transplant, factors
contributing to mortality rate are treatment-
related; before that, factors are disease-re-
lated. Even without a transplant, these
patients will suffer from all sort of complica-
tions including organ failure, kidney damage,
infections, and secondary malignancies.’’ UK
clinician
‘‘For sure HRQL will be lower compared
with the general population due to psycho-
logical problems related to treatment they
received, as well as poor social functioning.’’
French clinician
‘‘Long-term HRQL depends more upon the
treatment which is given. Patients cured
through HSCT would have poorer HRQL than
those cured by chemotherapy. HRQL usually
improves at later follow-up time points.’’
German clinician
‘‘Some patients have chronic GVHD [graft-
versus-host disease] and this affects their
utility substantially. Those who do will not
approach normal utilities.’’ UK clinician
‘‘It is a question of GVHD mostly… If a
patient has been cured without transplant,
the HRQL is not very different from the
general population.’’ French clinician
‘‘The HRQL increases every year after
transplant, for at least 5 years. Of course,
patients would not achieve the same quality
of life as untreated patients. But it would
improve over time.’’ German clinician
3026 Adv Ther (2019) 36:3017–3029
hospital, somatic sequelae, psychological prob-
lems, cognitive dysfunction, disruption of social
activities, and infertility. Several participants
commented that HRQL may improve over time
in the years after a patient has achieved cure.
DISCUSSION
The concept of cure has become an important
element in healthcare decision-making in
recent years. Critically, in this disease area, the
lack of clarity regarding the definition of cure
for adult Ph- BCP-ALL makes it challenging to
interpret evidence about the long-term efficacy
and relative value of emerging agents. This
study was conducted using a Delphi approach
to analyze the expert opinions of clinicians
currently treating patients with ALL. The find-
ings highlight both areas of commonality
among experts from the three countries inclu-
ded, as well as areas where consensus could not
be reached.
Our research aligns with other studies
[16, 17], indicating that clinicians are hesitant
to define patients as definitively ‘‘cured’’
because of the risk of late relapse. Despite this,
participants were able to frame the concept of
cure as being inversely related to the probability
of relapse. Consistent with the results of a prior
study using a similar methodology that focused
specifically on patients with relapsed and
refractory ALL [17], long-term leukemia-free (or
in this study, ‘‘relapse-free’’) survival was seen as
key to the concept of cure. Our research com-
plements this previous study; the current study
has generated findings on the concept of cure
for patients in first hematological remission,
and in addition considered the impact of MRD
status and provided country-specific findings.
The duration of relapse-free survival after
which the potential for cure emerges also
aligned among this group of expert panelists: in
two of the three country-specific panels, there
was consensus that cure could begin to be
considered at 3 years’ RFS. The concept of a high
likelihood of cure for patients at 5 years’ RFS
was also agreed, most notably by all panels for
patients in population C (patients who are
MRD-positive and subsequently remain MRD-
positive).
When considering the likelihood of cure,
participants found it difficult to estimate cure
rates for patients with Ph- BCP-ALL, because
treatment options are rapidly evolving, the
condition is rare, and outcomes vary with age,
health status, and eligibility for HSCT. For
patients who are MRD-positive, and critically
who are eligible for HSCT, consensus among
each panel was that cure rates could be expected
in the range 30–50%, with considerably lower
rates of cure expected among those ineligible
for HSCT.
Reflecting the dependence of the probability
of cure on eligibility for HSCT, participants
pointed out the integral role of HSCT in current
clinical practice for patients who are MRD-pos-
itive at CR1; they furthermore agreed that
allogeneic HSCT cannot be performed in all
patients. For patients who are ineligible for
HSCT on the basis of age, comorbidities, or
availability of a donor, participants agreed that
alternative treatments are needed. A number of
participants noted that cure is possible in some
patients with Ph- BCP-ALL who are MRD-pos-
itive, despite not receiving HSCT. There was
some speculation about the future role of
immunotherapy in patients who have MRD-
positive status at CR1. This was discussed as an
important option for achieving MRD-negative
status, but there was uncertainty regarding the
long-term durability of responses to such
therapy.
Notably, participants generally agreed that
the concept of cure does not imply that ‘‘cured’’
patients are likely to revert to the mortality risk
and HRQL expectations of people who have not
suffered this disease. However, mortality rates
among those considered to be cured from ALL
after HSCT were generally felt by panelists to
have improved in recent years (two of the three
panels agreed that the mortality risk was not
more than four times greater than the age- and
gender-matched general population). Moreover,
some clinicians opined that the impact of BCP-
ALL on HRQL varies between individual
patients, depending on whether they have long-
term complications of treatment, notably
Adv Ther (2019) 36:3017–3029 3027
chronic GVHD, and that the detrimental effects
of therapy may lessen in subsequent years.
A strength of this study is that the Delphi
methodology allows participants to exchange
information and discuss their experiences
before final responses are captured. Impor-
tantly, this method involves collecting both
quantitative estimates and qualitative explana-
tions of the rationales behind decisions and
opinions. This provides a nuanced understand-
ing of the concepts under consideration and the
reasons for agreement or lack thereof.
We also recognize the limitations of this
study, particularly with respect to the size of the
panels and how representative these are of the
country-specific clinician community (i.e., only
four or five participants provided their opin-
ions, to represent a country-wide perspective).
We do, however, consider these panel sizes to be
adequate to provide meaningful results, given
the small and specialist nature of the clinical
community treating adults with ALL in each
country.
CONCLUSIONS
This study offers quantitative and qualitative
information on the concept of cure in adults
with BCP-ALL in hematologic CR with or
without MRD—from the points of view of
clinicians in three Western European coun-
tries—with the aim of informing evaluation of
the clinical and economic benefits of emerging
novel therapeutic agents for ALL, specifically
immunotherapies. Expert clinicians defined the
threshold for reasonable probability of cure for
this disease and patient population on the basis
of 3–5 years’ RFS. The likelihood of cure in
patients with MRD was described as dependent
on eligibility for HSCT, with clinicians consis-
tently suggesting that alternative therapies are
needed for those who are ineligible. Cure was
associated with increased mortality risk and
negative impacts on HRQL (compared with the
general population), critically as a consequence
of treatment.
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